{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:29:49Z","timestamp":1781483389061,"version":"3.54.1"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","award":["SUB.D.260.22.016"],"award-info":[{"award-number":["SUB.D.260.22.016"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11033-022-07543-6","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T17:40:55Z","timestamp":1653414055000},"page":"9929-9945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular relation between biological stress and carcinogenesis"],"prefix":"10.1007","volume":"49","author":[{"given":"Katarzyna","family":"Rakoczy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Szlasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Saczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-5440","authenticated-orcid":false,"given":"Julita","family":"Kulbacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"issue":"2","key":"7543_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/00050069708257358","volume":"32","author":"S Edelman","year":"1997","unstructured":"Edelman S, Kidman AD (1997) Mind and cancer: is there a relationship?\u2014A review of evidence. Aust Psychol 32(2):79\u201385. https:\/\/doi.org\/10.1080\/00050069708257358","journal-title":"Aust Psychol"},{"issue":"12","key":"7543_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/1759-7714.12890","volume":"9","author":"M Chen","year":"2018","unstructured":"Chen M, Xie S (2018) Therapeutic targeting of cellular stress responses in cancer. Thoracic Cancer 9(12):1575\u20131582. https:\/\/doi.org\/10.1111\/1759-7714.12890","journal-title":"Thoracic Cancer"},{"issue":"10","key":"7543_CR3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0959-8049(02)00099-0","volume":"38","author":"SO Dalton","year":"2002","unstructured":"Dalton SO, Boesen EH, Ross L, Schapiro IR, Johansen C (2002) Mind and cancer: do psychological factors cause cancer? Eur J Cancer 38(10):1313\u20131323. https:\/\/doi.org\/10.1016\/S0959-8049(02)00099-0","journal-title":"Eur J Cancer"},{"issue":"1\u20132","key":"7543_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.canlet.2012.03.032","volume":"327","author":"AG Georgakilas","year":"2012","unstructured":"Georgakilas AG (2012) Oxidative stress, DNA damage and repair in carcinogenesis: Have we established a connection? Cancer Lett 327(1\u20132):3\u20134. https:\/\/doi.org\/10.1016\/j.canlet.2012.03.032","journal-title":"Cancer Lett"},{"issue":"2","key":"7543_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/cas.13455","volume":"109","author":"H Kitao","year":"2018","unstructured":"Kitao H et al (2018) DNA replication stress and cancer chemotherapy. Cancer Sci 109(2):264\u2013271. https:\/\/doi.org\/10.1111\/cas.13455","journal-title":"Cancer Sci"},{"issue":"4","key":"7543_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2215-0366(17)30014-7","volume":"4","author":"MJ Cordova","year":"2017","unstructured":"Cordova MJ, Riba MB, Spiegel D (2017) Post-traumatic stress disorder and cancer. Lancet Psych 4(4):330\u2013338. https:\/\/doi.org\/10.1016\/S2215-0366(17)30014-7","journal-title":"Lancet Psych"},{"issue":"1","key":"7543_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.arr.2012.10.004","volume":"12","author":"V Sosa","year":"2013","unstructured":"Sosa V, Molin\u00e9 T, Somoza R, Paciucci R, Kondoh H, LLeonart ME (2013) Oxidative stress and cancer: an overview. Ageing Res Rev 12(1):376\u2013390. https:\/\/doi.org\/10.1016\/j.arr.2012.10.004","journal-title":"Ageing Res Rev"},{"issue":"3","key":"7543_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1017\/S1478951511000897","volume":"10","author":"JK Rustad","year":"2012","unstructured":"Rustad JK, David D, Currier MB (2012) Cancer and post-traumatic stress disorder: diagnosis, pathogenesis and treatment considerations. Palliat Support Care 10(3):213\u2013223. https:\/\/doi.org\/10.1017\/S1478951511000897","journal-title":"Palliat Support Care"},{"key":"7543_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret M, Halazonetis TD (2015) DNA replication stress as a hallmark of cancer. Annu Rev Pathol Mech Dis 10:425\u2013448. https:\/\/doi.org\/10.1146\/annurev-pathol-012414-040424","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"1","key":"7543_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/039463201102400101","volume":"24","author":"CM Conti","year":"2011","unstructured":"Conti CM, Maccauro G, Fulcheri M (2011) Psychological stress and cancer. Int J Immunopathol Pharmacol 24(1):1\u20135. https:\/\/doi.org\/10.1177\/039463201102400101","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"7543_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/J.FREERADBIOMED.2010.09.016","volume":"49","author":"J Bylund","year":"2010","unstructured":"Bylund J, Brown KL, Movitz C, Dahlgren C, Karlsson A (2010) Intracellular generation of superoxide by the phagocyte NADPH oxidase: How, where, and what for? Free Radic Biol Med 49(12):1834\u20131845. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2010.09.016","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"7543_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3109\/07388551.2010.527823","volume":"31","author":"A Agarwal","year":"2011","unstructured":"Agarwal A, Banerjee A, Banerjee UC (2011) Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling. Crit Rev Biotechnol 31(3):264\u2013280. https:\/\/doi.org\/10.3109\/07388551.2010.527823","journal-title":"Crit Rev Biotechnol"},{"issue":"2","key":"7543_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/J.TOXLET.2011.06.003","volume":"205","author":"Q Zhang","year":"2011","unstructured":"Zhang Q et al (2011) Dihydrolipoamide dehydrogenase and cAMP are associated with cadmium-mediated Leydig cell damage. Toxicol Lett 205(2):183\u2013189. https:\/\/doi.org\/10.1016\/J.TOXLET.2011.06.003","journal-title":"Toxicol Lett"},{"issue":"6","key":"7543_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/J.TPLANTS.2011.03.007","volume":"16","author":"R Mitter","year":"2011","unstructured":"Mitter R et al (2011) ROS signaling: the new wave? Trends Plant Sci. 16(6):300\u2013309. https:\/\/doi.org\/10.1016\/J.TPLANTS.2011.03.007","journal-title":"Trends Plant Sci."},{"issue":"10","key":"7543_CR15","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24(10):R453. https:\/\/doi.org\/10.1016\/j.cub.2014.03.034","journal-title":"Curr Biol"},{"issue":"5619","key":"7543_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.1080405","volume":"300","author":"ZA Wood","year":"2003","unstructured":"Wood ZA, Poole LB, Karplus PA (2003) Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300(5619):650\u2013653. https:\/\/doi.org\/10.1126\/science.1080405","journal-title":"Science"},{"issue":"11","key":"7543_CR17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/J.BCP.2006.04.011","volume":"72","author":"G Gloire","year":"2006","unstructured":"Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72(11):1493\u20131505. https:\/\/doi.org\/10.1016\/J.BCP.2006.04.011","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"7543_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.taap.2009.11.028","volume":"254","author":"JE Klaunig","year":"2011","unstructured":"Klaunig JE, Wang Z, Pu X, Zhou S (2011) Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 254(2):86\u201399. https:\/\/doi.org\/10.1016\/j.taap.2009.11.028","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"7543_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1046\/J.1468-3083.2003.00751.X","volume":"17","author":"S Briganti","year":"2003","unstructured":"Briganti S, Picardo M (2003) Antioxidant activity, lipid peroxidation and skin diseases. What\u2019s new. J Eur Acad Dermatol Venereol 17(6):663\u2013669. https:\/\/doi.org\/10.1046\/J.1468-3083.2003.00751.X","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"7543_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1164\/RCCM.200212-1479SO","volume":"167","author":"K Vl","year":"2003","unstructured":"Vl K, Jd C (2003) Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 167(12):1600\u20131619. https:\/\/doi.org\/10.1164\/RCCM.200212-1479SO","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"7543_CR21","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.7314\/APJCP.2014.15.11.4405","volume":"15","author":"G Rk","year":"2014","unstructured":"Rk G et al (2014) Oxidative stress and antioxidants in disease and cancer: a review. Asian Pac J Cancer Prev 15(11):4405\u20134409. https:\/\/doi.org\/10.7314\/APJCP.2014.15.11.4405","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"7543_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1067\/MHL.2001.118298","volume":"30","author":"W Jn","year":"2001","unstructured":"Jn W, Jd P, Rl C (2001) Reactive oxygen species in acute respiratory distress syndrome. Heart Lung 30(5):370\u2013375. https:\/\/doi.org\/10.1067\/MHL.2001.118298","journal-title":"Heart Lung"},{"key":"7543_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/SAGEKE.2005.26.PE20","author":"LL Dugan","year":"2005","unstructured":"Dugan LL, Quick KL (2005) Reactive oxygen species and aging: evolving questions. Sci Aging Knowledge Environ. https:\/\/doi.org\/10.1126\/SAGEKE.2005.26.PE20","journal-title":"Sci. Aging Knowledge Environ"},{"key":"7543_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/J.1749-6632.1996.TB39057.X","volume":"786","author":"K Hensley","year":"1996","unstructured":"Hensley K et al (1996) Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer\u2019s disease-associated amyloid beta peptide. Ann NY Acad Sci 786:120\u2013134. https:\/\/doi.org\/10.1111\/J.1749-6632.1996.TB39057.X","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"7543_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/BJC.1997.363","volume":"76","author":"A Miyajima","year":"1997","unstructured":"Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M (1997) Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 76(2):206\u2013210. https:\/\/doi.org\/10.1038\/BJC.1997.363","journal-title":"Br J Cancer"},{"issue":"5","key":"7543_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/BCR315","volume":"3","author":"NS Brown","year":"2001","unstructured":"Brown NS, Bicknell R (2001) Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3(5):323\u2013327. https:\/\/doi.org\/10.1186\/BCR315","journal-title":"Breast Cancer Res."},{"issue":"5","key":"7543_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/carcin\/21.5.909","volume":"21","author":"RI Salganik","year":"2000","unstructured":"Salganik RI (2000) Dietary antioxidant depletion: enhancement of tumor apoptosis and inhibition of brain tumor growth in transgenic mice. Carcinogenesis 21(5):909. https:\/\/doi.org\/10.1093\/carcin\/21.5.909","journal-title":"Carcinogenesis"},{"issue":"1","key":"7543_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10937400701436460","volume":"11","author":"N Azad","year":"2008","unstructured":"Azad N, Rojanasakul Y, Vallyathan V (2008) Inflammation and lung cancer: roles of reactive oxygen\/nitrogen species. J Toxicol Environ Health B Crit Rev 11(1):1\u201315. https:\/\/doi.org\/10.1080\/10937400701436460","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"5","key":"7543_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/J.JHEP.2004.07.030","volume":"41","author":"DF Calvisi","year":"2004","unstructured":"Calvisi DF, Ladu S, Hironaka K, Factor VM, Thorgeirsson SS (2004) Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc\/TGF-alpha transgenic mouse model of liver cancer. J. Hepatol. 41(5):815\u2013822. https:\/\/doi.org\/10.1016\/J.JHEP.2004.07.030","journal-title":"J. Hepatol."},{"issue":"3","key":"7543_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/J.TAAP.2010.02.012","volume":"244","author":"D Sumi","year":"2010","unstructured":"Sumi D, Shinkai Y, Kumagai Y (2010) Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol Appl Pharmacol 244(3):385\u2013392. https:\/\/doi.org\/10.1016\/J.TAAP.2010.02.012","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"7543_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1159\/000082182","volume":"4","author":"AS Gukovskaya","year":"2004","unstructured":"Gukovskaya AS, Pandol SJ (2004) Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology 4(6):567\u2013586. https:\/\/doi.org\/10.1159\/000082182","journal-title":"Pancreatology"},{"issue":"9","key":"7543_CR32","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/CARCIN\/BGN167","volume":"29","author":"DW Chan","year":"2008","unstructured":"Chan DW et al (2008) Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29(9):1742\u20131750. https:\/\/doi.org\/10.1093\/CARCIN\/BGN167","journal-title":"Carcinogenesis"},{"issue":"5","key":"7543_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"2","key":"7543_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85\u201395. https:\/\/doi.org\/10.1038\/nrc2981","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"7543_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ccr.2008.11.003","volume":"14","author":"V Nogueira","year":"2008","unstructured":"Nogueira V et al (2008) Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14(6):458\u2013470. https:\/\/doi.org\/10.1016\/j.ccr.2008.11.003","journal-title":"Cancer Cell"},{"issue":"3","key":"7543_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ccr.2006.08.009","volume":"10","author":"D Trachootham","year":"2006","unstructured":"Trachootham D et al (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by \u03b2-phenylethyl isothiocyanate. Cancer Cell 10(3):241\u2013252. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.009","journal-title":"Cancer Cell"},{"issue":"12","key":"7543_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12):931\u2013947. https:\/\/doi.org\/10.1038\/nrd4002","journal-title":"Nat Rev Drug Discov"},{"key":"7543_CR38","unstructured":"J. B. Anna Janicka, Jolanta Szyma\u0144ska-Pasternak. [Polymorphisms in the oxidative stress-related genes and cancer risk]\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/25026746\/ (accessed Mar. 24, 2021)."},{"key":"7543_CR39","doi-asserted-by":"crossref","unstructured":"Al Zoubi, M, Aljabali, A (2021) Polymorphisms, antioxidant genes, and cancer. In Cancer. Elsevier, pp. 101\u2013110.","DOI":"10.1016\/B978-0-12-819547-5.00010-9"},{"issue":"5","key":"7543_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2174\/1574888X11666151203223512","volume":"11","author":"L Potze","year":"2016","unstructured":"Potze L, di Franco S, Kessler JH, Stassi G, Medema JP (2016) Betulinic acid kills colon cancer stem cells. Curr Stem Cell Res Ther 11(5):427\u2013433. https:\/\/doi.org\/10.2174\/1574888X11666151203223512","journal-title":"Curr Stem Cell Res Ther"},{"issue":"4","key":"7543_CR41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3892\/IJO.2017.4091","volume":"51","author":"KA Kang","year":"2017","unstructured":"Kang KA et al (2017) Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. Int J Oncol 51(4):1169\u20131178. https:\/\/doi.org\/10.3892\/IJO.2017.4091","journal-title":"Int J Oncol"},{"issue":"1","key":"7543_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/JNC.14250","volume":"144","author":"Z Zhu","year":"2018","unstructured":"Zhu Z, Du S, Du Y, Ren J, Ying G, Yan Z (2018) Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. J Neurochem 144(1):93\u2013104. https:\/\/doi.org\/10.1111\/JNC.14250","journal-title":"J Neurochem"},{"issue":"24","key":"7543_CR43","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1242\/JCS.058537","volume":"122","author":"SK Niture","year":"2009","unstructured":"Niture SK, Jain AK, Jaiswal AK (2009) Antioxidant-induced modification of INrf2 cysteine 151 and PKC-\u03b4-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci 122(24):4452\u20134464. https:\/\/doi.org\/10.1242\/JCS.058537","journal-title":"J Cell Sci"},{"issue":"8","key":"7543_CR44","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/IJC.25522","volume":"128","author":"F Crea","year":"2011","unstructured":"Crea F, Serrat MAD, Hurt EM, Thomas SB, Danesi R, Farrar WL (2011) BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 128(8):1946\u20131954. https:\/\/doi.org\/10.1002\/IJC.25522","journal-title":"Int J Cancer"},{"key":"7543_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep21382","author":"Z Liu","year":"2016","unstructured":"Liu Z et al (2016) Mark4 promotes oxidative stress and inflammation via binding to PPAR\u03b3 and activating NF-\u03baB pathway in mice adipocytes. Sci Rep. https:\/\/doi.org\/10.1038\/srep21382","journal-title":"Sci Rep"},{"key":"7543_CR46","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/J.BBI.2012.06.015","volume":"30","author":"ND Powell","year":"2013","unstructured":"Powell ND, Tarr AJ, Sheridan JF (2013) Psychosocial stress and inflammation in cancer. Brain Behav Immun 30:S41\u2013S47. https:\/\/doi.org\/10.1016\/J.BBI.2012.06.015","journal-title":"Brain Behav Immun"},{"issue":"6","key":"7543_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/10799893.2017.1369121","volume":"37","author":"G Nur","year":"2017","unstructured":"Nur G, Naz\u0131ro\u011flu M, Deveci HA (2017) Synergic prooxidant, apoptotic and TRPV1 channel activator effects of alpha-lipoic acid and cisplatin in MCF-7 breast cancer cells. J Recept Signal Transduct 37(6):569\u2013577. https:\/\/doi.org\/10.1080\/10799893.2017.1369121","journal-title":"J Recept Signal Transduct"},{"issue":"11","key":"7543_CR48","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/J.FREERADBIOMED.2010.09.006","volume":"49","author":"S Reuter","year":"2010","unstructured":"Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49(11):1603. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2010.09.006","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"7543_CR49","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/J.CELLSIG.2012.01.008","volume":"24","author":"PD Ray","year":"2012","unstructured":"Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24(5):981\u2013990. https:\/\/doi.org\/10.1016\/J.CELLSIG.2012.01.008","journal-title":"Cell Signal"},{"issue":"1","key":"7543_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/0192623309356453","volume":"38","author":"JE Klaunig","year":"2010","unstructured":"Klaunig JE, Kamendulis LM, Hocevar BA (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38(1):96\u2013109. https:\/\/doi.org\/10.1177\/0192623309356453","journal-title":"Toxicol Pathol"},{"issue":"8","key":"7543_CR51","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/J.1349-7006.2009.01207.X","volume":"100","author":"T Kamata","year":"2009","unstructured":"Kamata T (2009) Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100(8):1382\u20131388. https:\/\/doi.org\/10.1111\/J.1349-7006.2009.01207.X","journal-title":"Cancer Sci"},{"issue":"5","key":"7543_CR52","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/BIES.200900005","volume":"31","author":"M Los","year":"2009","unstructured":"Los M, Maddika S, Erb B, Schulze-Osthoff K (2009) Switching Akt: from survival signaling to deadly response. Bioessays 31(5):492\u2013495. https:\/\/doi.org\/10.1002\/BIES.200900005","journal-title":"Bioessays"},{"issue":"7","key":"7543_CR53","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/J.CELL.2007.06.009","volume":"129","author":"M Bd","year":"2007","unstructured":"Bd M, Lc C (2007) AKT\/PKB signaling: navigating downstream. Cell 129(7):1261\u20131274. https:\/\/doi.org\/10.1016\/J.CELL.2007.06.009","journal-title":"Cell"},{"issue":"50","key":"7543_CR54","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1038\/SJ.ONC.1209097","volume":"24","author":"P Dr","year":"2005","unstructured":"Dr P, Cb T (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24(50):7435\u20137442. https:\/\/doi.org\/10.1038\/SJ.ONC.1209097","journal-title":"Oncogene"},{"issue":"6\u20137","key":"7543_CR55","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/J.BBABIO.2015.02.012","volume":"1847","author":"P Korge","year":"2015","unstructured":"Korge P, Calmettes G, Weiss JN (2015) Increased reactive oxygen species production during reductive stress: the roles of mitochondrial glutathione and thioredoxin reductases. Biochim Biophys Acta 1847(6\u20137):514\u2013525. https:\/\/doi.org\/10.1016\/J.BBABIO.2015.02.012","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"7543_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/J.CELREP.2016.06.025","volume":"16","author":"S Maity","year":"2016","unstructured":"Maity S et al (2016) Oxidative homeostasis regulates the response to reductive endoplasmic reticulum stress through translation control. Cell Rep 16(3):851\u2013865. https:\/\/doi.org\/10.1016\/J.CELREP.2016.06.025","journal-title":"Cell Rep"},{"issue":"11","key":"7543_CR57","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1158\/2159-8290.CD-21-0558","volume":"11","author":"A Tasdogan","year":"2021","unstructured":"Tasdogan A, Ubellacker JM, Morrison SJ (2021) Redox regulation in cancer cells during metastasis. Cancer Discov 11(11):2682\u20132692. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0558","journal-title":"Cancer Discov"},{"issue":"1","key":"7543_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1079\/BJN2001435","volume":"87","author":"B Lipinski","year":"2002","unstructured":"Lipinski B (2002) Evidence in support of a concept of reductive stress. Br J Nutr 87(1):93\u201394. https:\/\/doi.org\/10.1079\/BJN2001435","journal-title":"Br J Nutr"},{"issue":"11","key":"7543_CR59","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1089\/ARS.2011.4123","volume":"16","author":"DE Handy","year":"2012","unstructured":"Handy DE, Loscalzo J (2012) Redox regulation of mitochondrial function. Antioxidants Redox Signal 16(11):1323\u20131367. https:\/\/doi.org\/10.1089\/ARS.2011.4123","journal-title":"Antioxidants Redox Signal"},{"issue":"4","key":"7543_CR60","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1096\/FJ.11-199869","volume":"26","author":"H Zhang","year":"2012","unstructured":"Zhang H et al (2012) Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J 26(4):1442\u20131451. https:\/\/doi.org\/10.1096\/FJ.11-199869","journal-title":"FASEB J"},{"issue":"12","key":"7543_CR61","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1089\/ARS.2009.2513","volume":"11","author":"EH Sarsour","year":"2009","unstructured":"Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, Goswami PC (2009) Redox control of the cell cycle in health and disease. Antioxidants Redox Signal 11(12):2985\u20133011. https:\/\/doi.org\/10.1089\/ARS.2009.2513","journal-title":"Antioxidants Redox Signal"},{"issue":"2","key":"7543_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/S12013-011-9320-3","volume":"67","author":"GR Buettner","year":"2011","unstructured":"Buettner GR, Wagner BA, Rodgers VGJ (2011) Quantitative redox biology: an approach to understand the role of reactive species in defining the cellular redox environment. Cell Biochem. Biophys. 67(2):477\u2013483. https:\/\/doi.org\/10.1007\/S12013-011-9320-3","journal-title":"Cell Biochem. Biophys."},{"issue":"9","key":"7543_CR63","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrm2240","volume":"8","author":"M Giorgio","year":"2007","unstructured":"Giorgio M, Trinei M, Migliaccio E, Pelicci PG (2007) Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat. Rev. Mol. Cell Biol. 8(9):722\u2013728. https:\/\/doi.org\/10.1038\/nrm2240","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"18","key":"7543_CR64","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1089\/ARS.2019.7803\/ASSET\/IMAGES\/LARGE\/ARS.2019.7803_FIGURE8.JPEG","volume":"32","author":"W Xiao","year":"2020","unstructured":"Xiao W, Loscalzo J (2020) Metabolic responses to reductive stress. Antioxidants Redox Signal 32(18):1330\u20131347. https:\/\/doi.org\/10.1089\/ARS.2019.7803\/ASSET\/IMAGES\/LARGE\/ARS.2019.7803_FIGURE8.JPEG","journal-title":"Antioxidants Redox Signal"},{"issue":"1","key":"7543_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.CANLET.2015.01.013","volume":"359","author":"IL Iba\u00f1ez","year":"2015","unstructured":"Iba\u00f1ez IL, Notcovich C, Catalano PN, Bellino MG, Dur\u00e1n H (2015) The redox-active nanomaterial toolbox for cancer therapy. Cancer Lett 359(1):9\u201319. https:\/\/doi.org\/10.1016\/J.CANLET.2015.01.013","journal-title":"Cancer Lett"},{"issue":"5","key":"7543_CR66","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.2353\/AJPATH.2009.080900","volume":"175","author":"K Onuma","year":"2009","unstructured":"Onuma K et al (2009) Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am J Pathol 175(5):2171. https:\/\/doi.org\/10.2353\/AJPATH.2009.080900","journal-title":"Am J Pathol"},{"key":"7543_CR67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-540-72865-8_2","volume":"111","author":"M Endo","year":"2007","unstructured":"Endo M, Strano MS, Ajayan PM (2007) Potential applications of carbon nanotubes. Top Appl Phys 111:13\u201362. https:\/\/doi.org\/10.1007\/978-3-540-72865-8_2","journal-title":"Top Appl Phys"},{"issue":"6348","key":"7543_CR68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/354056a0","volume":"354","author":"S Iijima","year":"1991","unstructured":"Iijima S (1991) Helical microtubules of graphitic carbon. Nat. 354(6348):56\u201358. https:\/\/doi.org\/10.1038\/354056a0","journal-title":"Nat."},{"issue":"7","key":"7543_CR69","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/INORGANICS7070088","volume":"7","author":"M Contel","year":"2019","unstructured":"Contel M (2019) unconventional anticancer metallodrugs and strategies to improve their pharmacological profile. Inorganics 7(7):88. https:\/\/doi.org\/10.3390\/INORGANICS7070088","journal-title":"Inorganics"},{"issue":"6","key":"7543_CR70","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/NRM4002","volume":"16","author":"M Fragkos","year":"2015","unstructured":"Fragkos M, Ganier O, Coulombe P, M\u00e9chali M (2015) DNA replication origin activation in space and time. Nat Rev Mol Cell Biol 16(6):360\u2013374. https:\/\/doi.org\/10.1038\/NRM4002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"7543_CR71","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","volume":"79","author":"T Ubhi","year":"2019","unstructured":"Ubhi T, Brown GW (2019) Exploiting DNA replication stress for cancer treatment. Cancer Res 79(8):1730\u20131739. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3631","journal-title":"Cancer Res"},{"issue":"5","key":"7543_CR72","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","volume":"8","author":"P Kotsantis","year":"2018","unstructured":"Kotsantis P, Petermann E, Boulton SJ (2018) Mechanisms of oncogene-induced replication stress: jigsaw falling into place. Cancer Discov 8(5):537\u2013555. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1461","journal-title":"Cancer Discov"},{"issue":"1","key":"7543_CR73","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/NCB2897","volume":"16","author":"Z Mk","year":"2014","unstructured":"Mk Z, Ka C (2014) Causes and consequences of replication stress. Nat Cell Biol 16(1):2\u20139. https:\/\/doi.org\/10.1038\/NCB2897","journal-title":"Nat Cell Biol"},{"issue":"32","key":"7543_CR74","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1038\/ONC.2012.387","volume":"32","author":"J Rm","year":"2013","unstructured":"Rm J et al (2013) Increased replication initiation and conflicts with transcription underlie cyclin E-induced replication stress. Oncogene 32(32):3744\u20133753. https:\/\/doi.org\/10.1038\/ONC.2012.387","journal-title":"Oncogene"},{"issue":"7495","key":"7543_CR75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"Gad H et al (2014) MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508(7495):215\u2013221. https:\/\/doi.org\/10.1038\/nature13181","journal-title":"Nature"},{"issue":"11","key":"7543_CR76","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/0008-5472.CAN-08-4559","volume":"69","author":"W Zhu","year":"2009","unstructured":"Zhu W, DePamphilis ML (2009) Selective killing of cancer cells by suppression of geminin activity. Cancer Res. 69(11):4870\u20134877. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4559","journal-title":"Cancer Res."},{"issue":"24","key":"7543_CR77","doi-asserted-by":"publisher","first-page":"10310","DOI":"10.1158\/0008-5472.CAN-10-2062","volume":"70","author":"JJ Lin","year":"2010","unstructured":"Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A (2010) NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 70(24):10310\u201310320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2062","journal-title":"Cancer Res."},{"issue":"6","key":"7543_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/GENES11060642","volume":"11","author":"T Wilhelm","year":"2020","unstructured":"Wilhelm T, Said M, Naim V (2020) DNA replication stress and chromosomal instability: dangerous liaisons. Genes (Basel) 11(6):1\u201335. https:\/\/doi.org\/10.3390\/GENES11060642","journal-title":"Genes (Basel)"},{"key":"7543_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/S12943-018-0915-9","author":"B Donati","year":"2018","unstructured":"Donati B, Lorenzini E, Ciarrocchi A (2018) BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. https:\/\/doi.org\/10.1186\/S12943-018-0915-9","journal-title":"Mol Cancer"},{"issue":"6","key":"7543_CR80","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/J.MOLCEL.2020.04.034","volume":"78","author":"W Sy","year":"2020","unstructured":"Sy W et al (2020) Opposing functions of BRD4 isoforms in breast cancer. Mol Cell 78(6):1114-1132.e10. https:\/\/doi.org\/10.1016\/J.MOLCEL.2020.04.034","journal-title":"Mol Cell"},{"issue":"11","key":"7543_CR81","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1039\/C8MD00198G","volume":"9","author":"Y Duan","year":"2018","unstructured":"Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H (2018) Targeting Brd4 for cancer therapy: inhibitors and degraders. Medchemcomm 9(11):1779\u20131802. https:\/\/doi.org\/10.1039\/C8MD00198G","journal-title":"Medchemcomm"},{"issue":"7","key":"7543_CR82","doi-asserted-by":"publisher","first-page":"556","DOI":"10.7150\/ijms.15853","volume":"13","author":"HK Lau","year":"2016","unstructured":"Lau HK et al (2016) Association between interleukin-18 polymorphisms and hepatocellular carcinoma occurrence and clinical progression. Int J Med Sci 13(7):556\u2013561","journal-title":"Int J Med Sci"},{"issue":"1","key":"7543_CR83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/039463200802100113","volume":"21","author":"Q Li","year":"2008","unstructured":"Li Q et al (2008) Visiting a forest, but not a city, increases human natural killer activity and expression of anti-cancer proteins. Int J Immunopathol Pharmacol 21(1):117\u2013127. https:\/\/doi.org\/10.1177\/039463200802100113","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"7543_CR84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1721727X1000800209","volume":"8","author":"A Sancini","year":"2010","unstructured":"Sancini A et al (2010) Stress characteristics in different work conditions: is it possible to identify specificity of risk factors by the questionnaire method? Eur J Inflamm 8(2):117\u2013123. https:\/\/doi.org\/10.1177\/1721727X1000800209","journal-title":"Eur J Inflamm"},{"issue":"4","key":"7543_CR85","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/ijerph18041871","volume":"18","author":"DJ Bowen","year":"2021","unstructured":"Bowen DJ et al (2021) The role of stress in breast cancer incidence: risk factors, interventions, and directions for the future. Int J Environ Res Public Health 18(4):1871. https:\/\/doi.org\/10.3390\/ijerph18041871","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"7543_CR86","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/J.1365-2249.2010.04262.X","volume":"162","author":"B Rearte","year":"2010","unstructured":"Rearte B et al (2010) Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice. Clin. Exp. Immunol. 162(3):568\u2013577. https:\/\/doi.org\/10.1111\/J.1365-2249.2010.04262.X","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"7543_CR87","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1039\/C0PP00315H","volume":"10","author":"D Preise","year":"2011","unstructured":"Preise D, Scherz A, Salomon Y (2011) Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci 10(5):681\u2013688. https:\/\/doi.org\/10.1039\/C0PP00315H","journal-title":"Photochem Photobiol Sci"},{"issue":"2","key":"7543_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1721727X1000800204","volume":"8","author":"G-H Zhang","year":"2010","unstructured":"Zhang G-H, Liu Y-F, Hu H-Y (2010) Preparation and cytotoxicity effect of anti-hepatocellular carcinoma SCFV immunoliposome on hepatocarcinoma cell in vitro. Eur J Inflamm 8(2):75\u201382. https:\/\/doi.org\/10.1177\/1721727X1000800204","journal-title":"Eur J Inflamm"},{"issue":"24","key":"7543_CR89","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1158\/0008-5472.CAN-10-0775","volume":"70","author":"L Wang","year":"2010","unstructured":"Wang L, Yi T, Zhang W, Pardoll DM, Yu H (2010) IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70(24):10112\u201310120. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0775","journal-title":"Cancer Res"},{"issue":"9","key":"7543_CR90","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/JOM.0B013E318228115E","volume":"53","author":"M Reale","year":"2011","unstructured":"Reale M et al (2011) Effects of palladium nanoparticles on the cytokine release from peripheral blood mononuclear cells of palladium-sensitized women. J Occup Environ Med 53(9):1054\u20131060. https:\/\/doi.org\/10.1097\/JOM.0B013E318228115E","journal-title":"J Occup Environ Med"},{"issue":"3","key":"7543_CR91","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/S10880-010-9208-1","volume":"17","author":"TL Deshields","year":"2010","unstructured":"Deshields TL, Nanna SK (2010) Providing care for the \u2018whole patient\u2019 in the cancer setting: the psycho-oncology consultation model of patient care. J Clin Psychol Med Settings 17(3):249\u2013257. https:\/\/doi.org\/10.1007\/S10880-010-9208-1","journal-title":"J Clin Psychol Med Settings"},{"issue":"2","key":"7543_CR92","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1721727X1000800206","volume":"8","author":"SS Singh","year":"2010","unstructured":"Singh SS, Yadav SK, Haldar C (2010) Effect of glucocorticoid and melatonin on immune function of an indian tropical bird, perdicula asiatica: an in vivo and in vitro study. Eur J Inflamm 8(2):89\u201397. https:\/\/doi.org\/10.1177\/1721727X1000800206","journal-title":"Eur J Inflamm"},{"key":"7543_CR93","unstructured":"Immunologia\u2014Jakub Go\u0142\u0105b, Marek Jak\u00f3bisiak, Witold Lasek, Tomasz Stok\u0142osa, PWN. https:\/\/medbook.com.pl\/ksiazka\/pokaz\/id\/14792\/tytul\/immunologia-golab-jakobisiak-lasek-stoklosa-pwn (accessed Sep. 17, 2021)."},{"issue":"10","key":"7543_CR94","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S1470-2045(04)01597-9","volume":"5","author":"R Em","year":"2004","unstructured":"Em R, So N, Hk M (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5(10):617\u2013625. https:\/\/doi.org\/10.1016\/S1470-2045(04)01597-9","journal-title":"Lancet Oncol"},{"issue":"5","key":"7543_CR95","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1159\/000500683","volume":"65","author":"P Li","year":"2019","unstructured":"Li P, Dj B (2019) Cellular senescence and the immune system in cancer. Gerontology 65(5):505\u2013512. https:\/\/doi.org\/10.1159\/000500683","journal-title":"Gerontology"},{"issue":"4","key":"7543_CR96","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/J.ANAI.2020.08.020","volume":"125","author":"M Gd","year":"2020","unstructured":"Gd M (2020) Psychological stress, immune dysfunction, and allergy: opportunities for improved patient health. Ann Allergy Asthma Immunol 125(4):365\u2013366. https:\/\/doi.org\/10.1016\/J.ANAI.2020.08.020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"7543_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/S-2007-972703","volume":"18","author":"FM Perna","year":"1997","unstructured":"Perna FM, Schneiderman N, LaPerriere A (1997) Psychological stress, exercise and immunity. Int J Sport Med Suppl 18:1. https:\/\/doi.org\/10.1055\/S-2007-972703","journal-title":"Int J Sport Med Suppl"},{"issue":"1","key":"7543_CR98","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/J.1529-8019.2008.00166.X","volume":"21","author":"F Tausk","year":"2008","unstructured":"Tausk F, Elenkov I, Moynihan J (2008) Psychoneuroimmunology. Dermatol Ther 21(1):22\u201331. https:\/\/doi.org\/10.1111\/J.1529-8019.2008.00166.X","journal-title":"Dermatol Ther"},{"issue":"19\u201320","key":"7543_CR99","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1111\/JOCN.13662","volume":"26","author":"L Yh","year":"2017","unstructured":"Yh L, Cc K, Sf W, Sl H, Hy Y, Hy T (2017) Risk factors of post-traumatic stress symptoms in patients with cancer. J Clin Nurs 26(19\u201320):3137\u20133143. https:\/\/doi.org\/10.1111\/JOCN.13662","journal-title":"J Clin Nurs"},{"key":"7543_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2013.00122","author":"M Kangas","year":"2013","unstructured":"Kangas M (2013) DSM-5 trauma and stress-related disorders: implications for screening for cancer-related stress. Front Psych. https:\/\/doi.org\/10.3389\/FPSYT.2013.00122","journal-title":"Front Psych"},{"key":"7543_CR101","doi-asserted-by":"publisher","unstructured":"C. CM, M. G, and F. M, \u201cPsychological stress and cancer,\u201d Int. J. Immunopathol. Pharmacol., vol. 24, no. 1, pp. 1\u20135, 2011, doi: https:\/\/doi.org\/10.1177\/039463201102400101.","DOI":"10.1177\/039463201102400101"},{"issue":"4","key":"7543_CR102","doi-asserted-by":"publisher","first-page":"531","DOI":"10.7326\/0003-4819-80-4-531","volume":"80","author":"G Me","year":"1974","unstructured":"Me G, Ej G, Ad S (1974) Cyclophosphamide: use in practice. Ann Intern Med 80(4):531\u2013540. https:\/\/doi.org\/10.7326\/0003-4819-80-4-531","journal-title":"Ann Intern Med"},{"issue":"11","key":"7543_CR103","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/NRCLINONC.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6(11):638\u2013647. https:\/\/doi.org\/10.1038\/NRCLINONC.2009.146","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"7543_CR104","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000073350","volume":"65","author":"M Furlanut","year":"2003","unstructured":"Furlanut M, Franceschi L (2003) Pharmacology of ifosfamide. Oncology 65:2\u20136. https:\/\/doi.org\/10.1159\/000073350","journal-title":"Oncology"},{"issue":"8","key":"7543_CR105","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/JNCI\/80.8.556","volume":"80","author":"M Zalupski","year":"1988","unstructured":"Zalupski M, Baker LH (1988) Ifosfamide. J. Natl. Cancer Inst. 80(8):556\u2013566. https:\/\/doi.org\/10.1093\/JNCI\/80.8.556","journal-title":"J. Natl. Cancer Inst."},{"key":"7543_CR106","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/J.CLML.2011.02.006","volume":"11","author":"D Catovsky","year":"2011","unstructured":"Catovsky D, Else M, Richards S (2011) Chlorambucil\u2013still not bad: a reappraisal. Clin. Lymphoma. Myeloma Leuk. 11:S2. https:\/\/doi.org\/10.1016\/J.CLML.2011.02.006","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"issue":"9","key":"7543_CR107","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3109\/10428194.2016.1154956","volume":"57","author":"L Vidal","year":"2016","unstructured":"Vidal L et al (2016) Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL)\u2014a systematic review and meta-analysis of randomized trials. Leuk. Lymphoma 57(9):2047\u20132057. https:\/\/doi.org\/10.3109\/10428194.2016.1154956","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"7543_CR108","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0936-6555(94)80058-8","volume":"6","author":"AE Taylor","year":"1994","unstructured":"Taylor AE, Gore ME (1994) Chlorambucil for platinum-refractory ovarian cancer. Clin. Oncol. 6(3):177\u2013178. https:\/\/doi.org\/10.1016\/S0936-6555(94)80058-8","journal-title":"Clin. Oncol."},{"issue":"1","key":"7543_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/104345429000700110","volume":"7","author":"DL Betcher","year":"1990","unstructured":"Betcher DL, Burnham N (1990) Melphalan. J. Pediatr. Oncol. Nurs. 7(1):35\u201336. https:\/\/doi.org\/10.1177\/104345429000700110","journal-title":"J. Pediatr. Oncol. Nurs."},{"issue":"2","key":"7543_CR110","first-page":"354","volume":"11","author":"F Rutledge","year":"1968","unstructured":"Rutledge F (1968) Chemotherapy of ovarian cancer with melphalan. Clin. Obstet. Gynecol. 11(2):354\u2013366","journal-title":"Clin. Obstet. Gynecol."},{"key":"7543_CR111","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/J.CTRV.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Rhun EL (2020) How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat. Rev. 87:102029. https:\/\/doi.org\/10.1016\/J.CTRV.2020.102029","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"7543_CR112","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/J.KINT.2020.02.017","volume":"98","author":"A Alrohaibani","year":"2020","unstructured":"Alrohaibani A, Swetnam LA, Andeen NK (2020) Microangiopathy, lomustine, and karyomegalic mesangial cells. Kidney Int. 98(2):517. https:\/\/doi.org\/10.1016\/J.KINT.2020.02.017","journal-title":"Kidney Int."},{"key":"7543_CR113","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/J.EJPHAR.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740:364\u2013378. https:\/\/doi.org\/10.1016\/J.EJPHAR.2014.07.025","journal-title":"Eur. J. Pharmacol."},{"key":"7543_CR114","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/J.BIOORG.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S (2019) Cisplatin: the first metal based anticancer drug. Bioorg. Chem. 88:102925. https:\/\/doi.org\/10.1016\/J.BIOORG.2019.102925","journal-title":"Bioorg. Chem."},{"key":"7543_CR115","first-page":"132","volume":"17","author":"E Reed","year":"1997","unstructured":"Reed E (1997) Cisplatin. Cancer Chemother. Biol. Response Modif. 17:132\u2013138","journal-title":"Cancer Chemother. Biol. Response Modif."},{"issue":"1","key":"7543_CR116","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5326\/15473317-36-1-13","volume":"36","author":"F Le","year":"2000","unstructured":"Le F (2000) Carboplatin. J Am Anim Hosp Assoc 36(1):13\u201314. https:\/\/doi.org\/10.5326\/15473317-36-1-13","journal-title":"J Am Anim Hosp Assoc"},{"key":"7543_CR117","first-page":"40","volume":"87","author":"E Pujade-Lauraine","year":"2000","unstructured":"Pujade-Lauraine E, Guastalla JP, Vincent P (2000) Carboplatin in cancer of the ovary. Bull. Cancer 87:40\u201347","journal-title":"Bull. Cancer"},{"issue":"1","key":"7543_CR118","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1188\/19.CJON.68-75","volume":"23","author":"BB Roger","year":"2019","unstructured":"Roger BB et al (2019) Oxaliplatin: detection and management of hypersensitivity reactions. Clin. J. Oncol. Nurs. 23(1):68\u201375. https:\/\/doi.org\/10.1188\/19.CJON.68-75","journal-title":"Clin. J. Oncol. Nurs."},{"key":"7543_CR119","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1051\/MEDSCI\/2020191","volume":"36","author":"S Ta\u00efb","year":"2020","unstructured":"Ta\u00efb S, Durand J, Brunet I (2020) Oxaliplatin-induced peripheral neuropathy: how to create a barrier? Med. Sci. (Paris) 36:33\u201337. https:\/\/doi.org\/10.1051\/MEDSCI\/2020191","journal-title":"Med. Sci. (Paris)"},{"key":"7543_CR120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/SONC.2002.35524","volume":"29","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Misset J-L (2002) Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 29:11\u201320. https:\/\/doi.org\/10.1053\/SONC.2002.35524","journal-title":"Semin. Oncol."},{"issue":"2","key":"7543_CR121","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/104345429100800242","volume":"8","author":"DL Betcher","year":"1991","unstructured":"Betcher DL, Burnham N (1991) Thiotepa. J. Pediatr. Oncol. Nurs. 8(2):95\u201397. https:\/\/doi.org\/10.1177\/104345429100800242","journal-title":"J. Pediatr. Oncol. Nurs."},{"issue":"6","key":"7543_CR122","doi-asserted-by":"publisher","first-page":"e22085","DOI":"10.1002\/SYN.22085","volume":"73","author":"TC Alexander","year":"2019","unstructured":"Alexander TC et al (2019) Effects of thioTEPA chemotherapy on cognition and motor coordination. Synapse 73(6):e22085. https:\/\/doi.org\/10.1002\/SYN.22085","journal-title":"Synapse"},{"issue":"6","key":"7543_CR123","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2165\/00003495-199549060-00007","volume":"49","author":"CR Lee","year":"1995","unstructured":"Lee CR, Faulds D (1995) Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs 49(6):932\u2013953. https:\/\/doi.org\/10.2165\/00003495-199549060-00007","journal-title":"Drugs"},{"issue":"2","key":"7543_CR124","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0090-8258(02)00103-8","volume":"88","author":"N Keldsen","year":"2003","unstructured":"Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A (2003) Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol. Oncol. 88(2):118\u2013122. https:\/\/doi.org\/10.1016\/S0090-8258(02)00103-8","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"7543_CR125","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/JJCO\/HYE012","volume":"31","author":"IA Malik","year":"2001","unstructured":"Malik IA (2001) Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol 31(2):69\u201373. https:\/\/doi.org\/10.1093\/JJCO\/HYE012","journal-title":"Jpn J Clin Oncol"},{"issue":"51","key":"7543_CR126","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1055\/S-0028-1108180","volume":"99","author":"H Jaap","year":"1974","unstructured":"Jaap H (1974) Undesired side-effects of busulfan. Dtsch. Med. Wochenschr. 99(51):2614\u20132615. https:\/\/doi.org\/10.1055\/S-0028-1108180","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"1\u20132","key":"7543_CR127","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/J.0954-6820.1972.TB04789.X","volume":"192","author":"S Dahlgren","year":"1972","unstructured":"Dahlgren S, Holm G, Svanborg N, Watz R (1972) Clinical and morphological side-effects of busulfan (Myleran) treatment. Acta Med. Scand. 192(1\u20132):129\u2013135. https:\/\/doi.org\/10.1111\/J.0954-6820.1972.TB04789.X","journal-title":"Acta Med. Scand."},{"issue":"1","key":"7543_CR128","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/J.1365-4362.1976.TB05098.X","volume":"15","author":"SK Carter","year":"1976","unstructured":"Carter SK (1976) Dacarbazine. Int J Dermatol 15(1):59\u201361. https:\/\/doi.org\/10.1111\/J.1365-4362.1976.TB05098.X","journal-title":"Int J Dermatol"},{"issue":"5","key":"7543_CR129","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/CMR.0B013E3283649A97","volume":"23","author":"F Teimouri","year":"2013","unstructured":"Teimouri F, Nikfar S, Abdollahi M (2013) Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res. 23(5):381\u2013389. https:\/\/doi.org\/10.1097\/CMR.0B013E3283649A97","journal-title":"Melanoma Res."},{"issue":"4","key":"7543_CR130","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/106002808702100403","volume":"21","author":"TJ Van Mouwerik","year":"1987","unstructured":"Van Mouwerik TJ, Caines PM, Ballentine R (1987) Amsacrine evaluation. Drug Intell. Clin. Pharm. 21(4):330\u2013334. https:\/\/doi.org\/10.1177\/106002808702100403","journal-title":"Drug Intell. Clin. Pharm."},{"issue":"11","key":"7543_CR131","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/0145-2126(86)90331-0","volume":"10","author":"PA Cassileth","year":"1986","unstructured":"Cassileth PA, Gale RP (1986) Amsacrine: a review. Leuk Res 10(11):1257\u20131265. https:\/\/doi.org\/10.1016\/0145-2126(86)90331-0","journal-title":"Leuk Res"},{"key":"7543_CR132","doi-asserted-by":"publisher","unstructured":"Evaluation of an antineoplastic agent. Dactinomycin (Cosmegen). JAMA, 196 (4), 353\u2013354, 1966. doi: https:\/\/doi.org\/10.1001\/JAMA.1966.03100170095031.","DOI":"10.1001\/JAMA.1966.03100170095031"},{"issue":"6","key":"7543_CR133","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/J.1600-0773.1993.TB01357.X","volume":"73","author":"S Auberson","year":"1993","unstructured":"Auberson S, Mauger AB, Lundberg JM (1993) Dactinomycin analogues as neurokinin-2 receptor antagonists. Pharmacol. Toxicol. 73(6):311\u2013314. https:\/\/doi.org\/10.1111\/J.1600-0773.1993.TB01357.X","journal-title":"Pharmacol. Toxicol."},{"issue":"6","key":"7543_CR134","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/0003-4819-81-6-795","volume":"81","author":"SD Spivack","year":"1974","unstructured":"Spivack SD (1974) Drugs 5 years later: procarbazine. Ann Intern Med 81(6):795\u2013800. https:\/\/doi.org\/10.7326\/0003-4819-81-6-795","journal-title":"Ann Intern Med"},{"issue":"1","key":"7543_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-1110(78)90009-X","volume":"55","author":"IP Lee","year":"1978","unstructured":"Lee IP, Dixon RL (1978) Mutagenicity, carcinogenicity and teratogenicity of procarbazine. Mutat Res 55(1):1\u201314. https:\/\/doi.org\/10.1016\/0165-1110(78)90009-X","journal-title":"Mutat Res"},{"issue":"2","key":"7543_CR136","first-page":"75","volume":"18","author":"N Murakami","year":"1978","unstructured":"Murakami N, Takayanagi T, Matsuoka Y, Sobue I (1978) Vincristine neuropathy following acute leukemia therapy (author\u2019s transl). Clin Neurol 18(2):75\u201381","journal-title":"Clin Neurol"},{"issue":"3","key":"7543_CR137","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/S00280-019-03884-5","volume":"84","author":"ML Madsen","year":"2019","unstructured":"Madsen ML, Due H, Ejskj\u00e6r N, Jensen P, Madsen J, Dybk\u00e6r K (2019) Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother. Pharmacol. 84(3):471\u2013485. https:\/\/doi.org\/10.1007\/S00280-019-03884-5","journal-title":"Cancer Chemother. Pharmacol."},{"key":"7543_CR138","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/J.CRITREVONC.2017.04.004","volume":"114","author":"ME van de Velde","year":"2017","unstructured":"van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH (2017) Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit. Rev. Oncol. Hematol. 114:114\u2013130. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2017.04.004","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"7543_CR139","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/S13312-020-1866-Y","volume":"57","author":"A Chakraborti","year":"2020","unstructured":"Chakraborti A, Sahi PK (2020) Vinblastine-induced acral hyperpigmentation. Indian Pediatr. 57(6):581\u2013582. https:\/\/doi.org\/10.1007\/S13312-020-1866-Y","journal-title":"Indian Pediatr."},{"issue":"2","key":"7543_CR140","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/TCR.201090001","volume":"10","author":"S Yokoshima","year":"2010","unstructured":"Yokoshima S, Tokuyama H, Fukuyama T (2010) Total synthesis of (+)-vinblastine: control of the stereochemistry at C18\u2019. Chem. Rec. 10(2):101\u2013118. https:\/\/doi.org\/10.1002\/TCR.201090001","journal-title":"Chem. Rec."},{"issue":"4","key":"7543_CR141","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00003088-198712040-00001","volume":"12","author":"PI Clark","year":"1987","unstructured":"Clark PI, Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12(4):223\u2013252. https:\/\/doi.org\/10.2165\/00003088-198712040-00001","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"7543_CR142","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/S00280-004-0858-2","volume":"55","author":"K Marigny","year":"2005","unstructured":"Marigny K, Aubin F, Burgot G, Gall EL, Gandemer V (2005) Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemother. Pharmacol. 55(3):244\u2013250. https:\/\/doi.org\/10.1007\/S00280-004-0858-2","journal-title":"Cancer Chemother. Pharmacol."},{"key":"7543_CR143","first-page":"95","volume":"19","author":"A van der Gaast","year":"1992","unstructured":"van der Gaast A, Splinter TAW (1992) Teniposide (VM-26) in ovarian cancer: a review. Semin Oncol 19:95\u201397","journal-title":"Semin Oncol"},{"issue":"12","key":"7543_CR144","first-page":"1455","volume":"68","author":"PJ O\u2019Dwyer","year":"1984","unstructured":"O\u2019Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S (1984) Teniposide. A review of 12 years of experience. Cancer Treat Rep 68(12):1455\u20131466","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"7543_CR145","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/J.1525-1438.2007.01003.X","volume":"17","author":"S Ackermann","year":"2007","unstructured":"Ackermann S, Beckmann MW, Thiel F, Bogenrieder T (2007) Topotecan in cervical cancer. Int. J. Gynecol. Cancer 17(6):1215\u20131223. https:\/\/doi.org\/10.1111\/J.1525-1438.2007.01003.X","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"7543_CR146","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1517\/14656566.8.2.227","volume":"8","author":"LM Randall-Whitis","year":"2007","unstructured":"Randall-Whitis LM, Monk BJ (2007) Topotecan in the management of cervical cancer. Expert Opin Pharmacother 8(2):227\u2013236. https:\/\/doi.org\/10.1517\/14656566.8.2.227","journal-title":"Expert Opin Pharmacother"},{"key":"7543_CR147","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/J.PHRS.2019.104398","volume":"148","author":"C Bally","year":"2019","unstructured":"Bally C (2019) Irinotecan: 25 years of cancer treatment. Pharmacol. Res. 148:104398. https:\/\/doi.org\/10.1016\/J.PHRS.2019.104398","journal-title":"Pharmacol. Res."},{"issue":"14","key":"7543_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21144919","volume":"21","author":"M Kciuk","year":"2020","unstructured":"Kciuk M, Marciniak B, Kontek R (2020) Irinotecan-still an important player in cancer chemotherapy: a comprehensive overview. Int. J. Mol. Sci. 21(14):1\u201321. https:\/\/doi.org\/10.3390\/IJMS21144919","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"7543_CR149","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/J.EURURO.2020.01.026","volume":"77","author":"H Beltran","year":"2020","unstructured":"Beltran H, Morris MJ (2020) Docetaxel for early prostate cancer: what have we learned? Eur. Urol. 77(5):573\u2013575. https:\/\/doi.org\/10.1016\/J.EURURO.2020.01.026","journal-title":"Eur. Urol."},{"issue":"8","key":"7543_CR150","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/GENES10080599","volume":"10","author":"R Varnai","year":"2019","unstructured":"Varnai R, Koskinen LM, M\u00e4ntyl\u00e4 LE, Szabo I, FitzGerald LM, Sipeky C (2019) Pharmacogenomic biomarkers in docetaxel treatment of prostate cancer: from discovery to implementation. Genes (Basel) 10(8):599. https:\/\/doi.org\/10.3390\/GENES10080599","journal-title":"Genes (Basel)"},{"issue":"12","key":"7543_CR151","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/BIOM9120789","volume":"9","author":"TMA Samaan","year":"2019","unstructured":"Samaan TMA, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D (2019) Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules 9(12):789. https:\/\/doi.org\/10.3390\/BIOM9120789","journal-title":"Biomolecules"},{"issue":"18","key":"7543_CR152","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/MBC.E14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA (2014) How taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677\u20132681. https:\/\/doi.org\/10.1091\/MBC.E14-04-0916","journal-title":"Mol Biol Cell"},{"issue":"13","key":"7543_CR153","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMC2000990","volume":"382","author":"V Di Nunno","year":"2020","unstructured":"Di Nunno V, Mollica V, Massari F (2020) Cabazitaxel in Metastatic Prostate Cancer. N. Engl. J. Med. 382(13):1286\u20131286. https:\/\/doi.org\/10.1056\/NEJMC2000990","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"7543_CR154","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMOA1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381(26):2506\u20132518. https:\/\/doi.org\/10.1056\/NEJMOA1911206","journal-title":"N. Engl. J. Med."},{"key":"7543_CR155","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/J.LEUKRES.2018.11.011","volume":"76","author":"B Marcellino","year":"2019","unstructured":"Marcellino B, Hoffman R, Mascarenhas J (2019) Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia? Leuk. Res. 76:94\u201395. https:\/\/doi.org\/10.1016\/J.LEUKRES.2018.11.011","journal-title":"Leuk. Res."},{"issue":"3","key":"7543_CR156","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2515\/THERAPIE\/2010023","volume":"65","author":"M Boisdron-Celle","year":"2010","unstructured":"Boisdron-Celle M, Le Guellec C (2010) Niveau de preuve du suivi th\u00e9rapeutique pharmacologique du 5-fluorouracile au d\u00e9cours de son administration dans le traitement des cancers des voies a\u00e9rodigestives sup\u00e9rieures et du cancer colorectal. Therapie 65(3):171\u2013176. https:\/\/doi.org\/10.2515\/THERAPIE\/2010023","journal-title":"Therapie"},{"issue":"3","key":"7543_CR157","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1872210513666190702165556","volume":"14","author":"G Patel","year":"2020","unstructured":"Patel G, Yadav BKN (2020) Study of 5-fluorouracil loaded chitosan nanoparticles for treatment of skin cancer. Recent Pat. Nanotechnol. 14(3):210\u2013224. https:\/\/doi.org\/10.2174\/1872210513666190702165556","journal-title":"Recent Pat. Nanotechnol."},{"issue":"1","key":"7543_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12272-017-0979-X","volume":"41","author":"Y Wei","year":"2018","unstructured":"Wei Y, Yang P, Cao S, Zhao L (2018) The combination of curcumin and 5-fluorouracil in cancer therapy. Arch. Pharm. Res. 41(1):1\u201313. https:\/\/doi.org\/10.1007\/S12272-017-0979-X","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"7543_CR159","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/BLOOD-2015-09-667675","volume":"127","author":"T Pa","year":"2016","unstructured":"Pa T et al (2016) Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303\u2013309. https:\/\/doi.org\/10.1182\/BLOOD-2015-09-667675","journal-title":"Blood"},{"issue":"5","key":"7543_CR160","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1177\/106002809102500512","volume":"25","author":"MA Hood","year":"1991","unstructured":"Hood MA, Finley RS (1991) Fludarabine: a review. DICP 25(5):518\u2013524. https:\/\/doi.org\/10.1177\/106002809102500512","journal-title":"DICP"},{"issue":"9","key":"7543_CR161","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/J.LEUKRES.2013.05.004","volume":"37","author":"J Lukenbill","year":"2013","unstructured":"Lukenbill J, Kalaycio M (2013) Fludarabine: a review of the clear benefits and potential harms. Leuk. Res. 37(9):986\u2013994. https:\/\/doi.org\/10.1016\/J.LEUKRES.2013.05.004","journal-title":"Leuk. Res."},{"issue":"6","key":"7543_CR162","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/THEONCOLOGIST.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694\u2013703. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.11-6-694","journal-title":"Oncologist"},{"issue":"1","key":"7543_CR163","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/03602537808993779","volume":"8","author":"BA Chabner","year":"1978","unstructured":"Chabner BA, Stoller RG, Hande K, Jacobs S, Young RC (1978) Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. Drug Metab. Rev. 8(1):107\u2013117. https:\/\/doi.org\/10.3109\/03602537808993779","journal-title":"Drug Metab. Rev."},{"issue":"7","key":"7543_CR164","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMOA1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629\u2013640. https:\/\/doi.org\/10.1056\/NEJMOA1612674","journal-title":"N Engl J Med"},{"issue":"14","key":"7543_CR165","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S et al (2020) Updated analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38(14):1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"7543_CR166","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1517\/13543780903071038","volume":"18","author":"S Spurgeon","year":"2009","unstructured":"Spurgeon S, Yu M, Phillips JD, Epner EM (2009) Cladribine: not just another purine analogue? Expert Opin Investig Drugs 18(8):1169\u20131181. https:\/\/doi.org\/10.1517\/13543780903071038","journal-title":"Expert Opin Investig Drugs"},{"key":"7543_CR167","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/10428194.2011.570395","volume":"52","author":"F Lauria","year":"2011","unstructured":"Lauria F, Cencini E, Forconi F (2011) Alternative methods of cladribine administration. Leuk. Lymphoma 52:34\u201337. https:\/\/doi.org\/10.3109\/10428194.2011.570395","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"7543_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","volume":"10","author":"TM Kadia","year":"2017","unstructured":"Kadia TM, Gandhi V (2017) Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev. Hematol. 10(1):1\u20138. https:\/\/doi.org\/10.1080\/17474086.2017.1262757","journal-title":"Expert Rev. Hematol."},{"issue":"28","key":"7543_CR169","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"D Kp","year":"2020","unstructured":"Kp D et al (2020) Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol 38(28):3282\u20133293. https:\/\/doi.org\/10.1200\/JCO.20.00256","journal-title":"J Clin Oncol"},{"issue":"5","key":"7543_CR170","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/NRD1724","volume":"4","author":"C-H Pui","year":"2005","unstructured":"Pui C-H, Jeha S, Kirkpatrick P (2005) Clofarabine. Nat. Rev. Drug Discov. 4(5):369\u2013370. https:\/\/doi.org\/10.1038\/NRD1724","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"7543_CR171","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/J.BCP.2009.06.094","volume":"78","author":"A Zhenchuk","year":"2009","unstructured":"Zhenchuk A, Lotfi K, Juliusson G, Albertioni F (2009) Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem. Pharmacol. 78(11):1351\u20131359. https:\/\/doi.org\/10.1016\/J.BCP.2009.06.094","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"7543_CR172","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0090-8258(03)00338-X","volume":"90","author":"DG Mutch","year":"2003","unstructured":"Mutch DG, Bloss JD (2003) Gemcitabine in cervical cancer. Gynecol. Oncol. 90(2):S8\u2013S15. https:\/\/doi.org\/10.1016\/S0090-8258(03)00338-X","journal-title":"Gynecol. Oncol."},{"issue":"32","key":"7543_CR173","doi-asserted-by":"publisher","first-page":"51301","DOI":"10.18632\/ONCOTARGET.10117","volume":"7","author":"H Ono","year":"2016","unstructured":"Ono H, Basson MD, Ito H (2016) P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Oncotarget 7(32):51301\u201351310. https:\/\/doi.org\/10.18632\/ONCOTARGET.10117","journal-title":"Oncotarget"},{"issue":"4","key":"7543_CR174","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/104345429000700406","volume":"7","author":"DL Betcher","year":"1990","unstructured":"Betcher DL, Burnham N (1990) Cytarabine. J. Pediatr. Oncol. Nurs. 7(4):154\u2013157. https:\/\/doi.org\/10.1177\/104345429000700406","journal-title":"J. Pediatr. Oncol. Nurs."},{"issue":"12","key":"7543_CR175","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/BIOM9120773","volume":"9","author":"B Salehi","year":"2019","unstructured":"Salehi B et al (2019) Liposomal cytarabine as cancer therapy: from chemistry to medicine. Biomolecules 9(12):773. https:\/\/doi.org\/10.3390\/BIOM9120773","journal-title":"Biomolecules"},{"key":"7543_CR176","doi-asserted-by":"publisher","first-page":"110461","DOI":"10.1016\/J.MSEC.2019.110461","volume":"108","author":"J Liao","year":"2020","unstructured":"Liao J et al (2020) A bio-responsive 6-mercaptopurine\/doxorubicin based \u2018Click Chemistry\u2019 polymeric prodrug for cancer therapy. Mater. Sci. Eng. C. Mater. Biol. Appl. 108:110461. https:\/\/doi.org\/10.1016\/J.MSEC.2019.110461","journal-title":"Mater. Sci. Eng. C. Mater. Biol. Appl."},{"issue":"6","key":"7543_CR177","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/BF00279977","volume":"40","author":"P Lafolie","year":"1991","unstructured":"Lafolie P, Hayder S, Bj\u00f6rk O, Peterson C (1991) Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia. Eur J Clin Pharmacol 40(6):599\u2013601. https:\/\/doi.org\/10.1007\/BF00279977","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"7543_CR178","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PAJ Speth","year":"1988","unstructured":"Speth PAJ, van Hoesel QGCM, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15(1):15\u201331. https:\/\/doi.org\/10.2165\/00003088-198815010-00002","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"7543_CR179","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S (2014) An overview of doxorubicin formulations in cancer therapy. J. Cancer Res. Ther. 10(4):853\u2013858. https:\/\/doi.org\/10.4103\/0973-1482.139267","journal-title":"J. Cancer Res. Ther."},{"issue":"2","key":"7543_CR180","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/J.BREAST.2011.12.012","volume":"21","author":"M Khasraw","year":"2012","unstructured":"Khasraw M, Bell R, Dang C (2012) Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21(2):142\u2013149. https:\/\/doi.org\/10.1016\/J.BREAST.2011.12.012","journal-title":"Breast"},{"key":"7543_CR181","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2000.S.012","author":"M Levine","year":"2000","unstructured":"Levine M (2000) Epirubicin in breast cancer: present and future. Clin Breast Cancer. https:\/\/doi.org\/10.3816\/CBC.2000.S.012","journal-title":"Clin. Breast Cancer"},{"issue":"5","key":"7543_CR182","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/106002809102500511","volume":"25","author":"SM Suzanne","year":"1991","unstructured":"Suzanne SM, Koeller JM (1991) Idarubicin: a second-generation anthracycline. DICP 25(5):505\u2013517. https:\/\/doi.org\/10.1177\/106002809102500511","journal-title":"DICP"},{"issue":"4","key":"7543_CR183","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2165\/00003495-199142040-00010","volume":"42","author":"LM Hollingshead","year":"1991","unstructured":"Hollingshead LM, Faulds D (1991) Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42(4):690\u2013719. https:\/\/doi.org\/10.2165\/00003495-199142040-00010","journal-title":"Drugs"},{"issue":"6","key":"7543_CR184","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543784.2010.485191","volume":"19","author":"A Dimou","year":"2010","unstructured":"Dimou A, Syrigos KN, Saif MW (2010) Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin. Investig. Drugs 19(6):723\u2013735. https:\/\/doi.org\/10.1517\/13543784.2010.485191","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"7543_CR185","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/S00345-011-0691-2","volume":"29","author":"C de Nunzio","year":"2011","unstructured":"de Nunzio C et al (2011) Long-term experience with early single Mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: Prospective, single-centre randomised trial. World J Urol 29(4):517\u2013521. https:\/\/doi.org\/10.1007\/S00345-011-0691-2","journal-title":"World J Urol"},{"issue":"34","key":"7543_CR186","doi-asserted-by":"publisher","first-page":"16307","DOI":"10.1039\/C8NR04142C","volume":"10","author":"RD Lin","year":"2018","unstructured":"Lin RD, Steinmetz NF (2018) Tobacco mosaic virus delivery of mitoxantrone for cancer therapy. Nanoscale 10(34):16307\u201316313. https:\/\/doi.org\/10.1039\/C8NR04142C","journal-title":"Nanoscale"},{"issue":"2","key":"7543_CR187","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/MED.21364","volume":"36","author":"BJ Evison","year":"2016","unstructured":"Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2016) Mitoxantrone, more than just another topoisomerase II poison. Med. Res. Rev. 36(2):248\u2013299. https:\/\/doi.org\/10.1002\/MED.21364","journal-title":"Med. Res. Rev."},{"issue":"6","key":"7543_CR188","doi-asserted-by":"publisher","first-page":"945","DOI":"10.7326\/0003-4819-90-6-945","volume":"90","author":"B Jm","year":"1979","unstructured":"Jm B, Sd R (1979) Bleomycin. Ann Intern Med 90(6):945. https:\/\/doi.org\/10.7326\/0003-4819-90-6-945","journal-title":"Ann Intern Med"},{"issue":"46","key":"7543_CR189","first-page":"737","volume":"84","author":"L Christensen","year":"1972","unstructured":"Christensen L (1972) Bleomycin, ein neues Antitumor-Antibiotikum zur Behandlung neoplastischer Krankheiten. Wien Klin Wochenschr 84(46):737\u2013743","journal-title":"Wien Klin Wochenschr"},{"key":"7543_CR190","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/J.EXPHEM.2020.09.196","volume":"91","author":"S Martinez-H\u00f8yer","year":"2020","unstructured":"Martinez-H\u00f8yer S, Karsan A (2020) Mechanisms of lenalidomide sensitivity and resistance. Exp. Hematol. 91:22\u201331. https:\/\/doi.org\/10.1016\/J.EXPHEM.2020.09.196","journal-title":"Exp. Hematol."},{"issue":"24","key":"7543_CR191","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1182\/BLOOD.2019001751","volume":"135","author":"CR Flower","year":"2020","unstructured":"Flower CR, Leonard JP, Flower NH (2020) Lenalidomide in follicular lymphoma. Blood 135(24):2133\u20132136. https:\/\/doi.org\/10.1182\/BLOOD.2019001751","journal-title":"Blood"},{"issue":"5","key":"7543_CR192","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/09540261.2017.1307168","volume":"29","author":"C Gesi","year":"2017","unstructured":"Gesi C, Carmassi C, Sancassiani F, Gadducci A, Dell\u2019Osso L (2017) Post-traumatic stress disorder in patients with ovarian cancer. Int. Rev. Psychiatry 29(5):403\u2013408. https:\/\/doi.org\/10.1080\/09540261.2017.1307168","journal-title":"Int. Rev. Psychiatry"},{"issue":"9","key":"7543_CR193","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/S00520-018-4146-9","volume":"26","author":"E Moschopoulou","year":"2018","unstructured":"Moschopoulou E, Hutchison I, Bhui K, Korszun A (2018) Post-traumatic stress in head and neck cancer survivors and their partners. Support. Care Cancer 26(9):3003\u20133011. https:\/\/doi.org\/10.1007\/S00520-018-4146-9","journal-title":"Support. Care Cancer"},{"key":"7543_CR194","doi-asserted-by":"publisher","DOI":"10.1186\/S40359-021-00515-8","author":"RY Hu","year":"2021","unstructured":"Hu RY et al (2021) Stress, coping strategies and expectations among breast cancer survivors in China: a qualitative study. BMC Psychol. https:\/\/doi.org\/10.1186\/S40359-021-00515-8","journal-title":"BMC Psychol."},{"issue":"9","key":"7543_CR195","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/CNCR.31943","volume":"125","author":"MH Antoni","year":"2019","unstructured":"Antoni MH, Dhabhar FS (2019) The impact of psychosocial stress and stress management on immune responses in patients with cancer. Cancer 125(9):1417\u20131431. https:\/\/doi.org\/10.1002\/CNCR.31943","journal-title":"Cancer"},{"issue":"16","key":"7543_CR196","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","volume":"23","author":"L Shaashua","year":"2017","unstructured":"Shaashua L et al (2017) Perioperative COX-2 and \u03b2-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clin Cancer Res 23(16):4651\u20134661. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0152","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7543_CR197","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000446114","volume":"104","author":"Y Gao","year":"2017","unstructured":"Gao Y, Zhou JJ, Zhu Y, Kosten T, Li DP (2017) Chronic unpredictable mild stress induces loss of GABA inhibition in corticotrophin-releasing hormone-expressing neurons through NKCC1 upregulation. Neuroendocrinology 104(2):194\u2013208. https:\/\/doi.org\/10.1159\/000446114","journal-title":"Neuroendocrinology"},{"issue":"2","key":"7543_CR198","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/S10549-012-2251-X","volume":"136","author":"JE Lavigne","year":"2012","unstructured":"Lavigne JE et al (2012) A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat 136(2):479\u2013486. https:\/\/doi.org\/10.1007\/S10549-012-2251-X","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"7543_CR199","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1200\/JCO.2003.08.025","volume":"21","author":"MJ Fisch","year":"2003","unstructured":"Fisch MJ et al (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 21(10):1937\u20131943. https:\/\/doi.org\/10.1200\/JCO.2003.08.025","journal-title":"J Clin Oncol"},{"issue":"5","key":"7543_CR200","doi-asserted-by":"publisher","first-page":"e0233412","DOI":"10.1371\/JOURNAL.PONE.0233412","volume":"15","author":"P Zhao","year":"2020","unstructured":"Zhao P et al (2020) Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: a randomized, controlled, double-blind trial. PLoS One 15(5):e0233412. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0233412","journal-title":"PLoS One"},{"issue":"5","key":"7543_CR201","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/GME.0B013E3181DBEE1B","volume":"17","author":"H Joffe","year":"2010","unstructured":"Joffe H et al (2010) Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause 17(5):908\u2013916. https:\/\/doi.org\/10.1097\/GME.0B013E3181DBEE1B","journal-title":"Menopause"},{"key":"7543_CR202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006911","author":"J Bradt","year":"2016","unstructured":"Bradt J, Dileo C, Magill L, Teague A (2016) Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006911","journal-title":"Cochrane Database Syst. Rev"},{"key":"7543_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-017-0791-Y","author":"FN Jacka","year":"2017","unstructured":"Jacka FN et al (2017) A randomised controlled trial of dietary improvement for adults with major depression (the \u2018SMILES\u2019 trial). BMC Med. https:\/\/doi.org\/10.1186\/S12916-017-0791-Y","journal-title":"BMC Med."},{"issue":"10","key":"7543_CR204","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1136\/GUTJNL-2016-311990","volume":"66","author":"M Song","year":"2017","unstructured":"Song M et al (2017) Marine \u03c9-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut 66(10):1790\u20131796. https:\/\/doi.org\/10.1136\/GUTJNL-2016-311990","journal-title":"Gut"},{"issue":"6","key":"7543_CR205","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/S00520-017-4019-7","volume":"26","author":"RJ Marker","year":"2017","unstructured":"Marker RJ, Cox-Martin E, Jankowski CM, Purcell WT, Peters JC (2017) Evaluation of the effects of a clinically implemented exercise program on physical fitness, fatigue, and depression in cancer survivors. Support. Care Cancer 26(6):1861\u20131869. https:\/\/doi.org\/10.1007\/S00520-017-4019-7","journal-title":"Support. Care Cancer"},{"key":"7543_CR206","doi-asserted-by":"publisher","DOI":"10.1177\/1534735420975852","author":"MC Hidde","year":"2020","unstructured":"Hidde MC, Leach HJ, Marker RJ, Peters JC, Purcell WT (2020) Effects of a clinic-based exercise program on sleep disturbance among cancer survivors. Integr Cancer Ther. https:\/\/doi.org\/10.1177\/1534735420975852","journal-title":"Integr. Cancer Ther."},{"issue":"3","key":"7543_CR207","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1534735415617021","volume":"15","author":"MC Janelsins","year":"2016","unstructured":"Janelsins MC et al (2016) YOCAS\u00a9\u00ae yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: investigating relationships between memory and sleep. Integr Cancer Ther 15(3):263\u2013271. https:\/\/doi.org\/10.1177\/1534735415617021","journal-title":"Integr Cancer Ther"},{"key":"7543_CR208","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419855134","author":"PJ Lin","year":"2019","unstructured":"Lin PJ et al (2019) Influence of yoga on cancer-related fatigue and on mediational relationships between changes in sleep and cancer-related fatigue: a nationwide, multicenter randomized controlled trial of yoga in cancer survivors. Integr Cancer Ther. https:\/\/doi.org\/10.1177\/1534735419855134","journal-title":"Integr. Cancer Ther."},{"issue":"4","key":"7543_CR209","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1177\/1534735418786797","volume":"17","author":"K Kim","year":"2018","unstructured":"Kim K, Lee S (2018) Intradermal acupuncture along with analgesics for pain control in advanced cancer cases: a pilot, randomized, patient-assessor-blinded, controlled trial. Integr Cancer Ther 17(4):1137\u20131143. https:\/\/doi.org\/10.1177\/1534735418786797","journal-title":"Integr Cancer Ther"},{"issue":"2","key":"7543_CR210","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/JAMAONCOL.2019.5233","volume":"6","author":"Y He","year":"2020","unstructured":"He Y et al (2020) Clinical evidence for association of acupuncture and acupressure with improved cancer pain: a systematic review and meta-analysis. JAMA Oncol 6(2):271\u2013278. https:\/\/doi.org\/10.1001\/JAMAONCOL.2019.5233","journal-title":"JAMA Oncol"},{"issue":"3","key":"7543_CR211","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"YX Chen","year":"2020","unstructured":"Chen YX et al (2020) Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol 5(3):267\u2013275. https:\/\/doi.org\/10.1016\/S2468-1253(19)30409-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"23","key":"7543_CR212","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.2016.71.0285","volume":"35","author":"MR Irwin","year":"2017","unstructured":"Irwin MR et al (2017) Tai Chi Chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol 35(23):2656. https:\/\/doi.org\/10.1200\/JCO.2016.71.0285","journal-title":"J Clin Oncol"},{"key":"7543_CR213","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1021\/jf103335w","volume":"58","author":"H Lu","year":"2010","unstructured":"Lu H et al (2010) Antitumor activity of capsaicin on human colon cancer cells in vitro and colo 205 tumor xenografts in vivo. J Agric Food Chem 58:1299\u20133005","journal-title":"J Agric Food Chem"},{"key":"7543_CR214","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3892\/mmr.2015.4623","volume":"13","author":"L Zheng","year":"2016","unstructured":"Zheng L et al (2016) Capsaicin enhances anti-proliferation efficacy of pirarubicin via activating TRPV1 and inhibiting PCNA nuclear translocation in 5637 cells. Mol Med Re 13:881\u2013887","journal-title":"Mol Med Re"},{"issue":"5","key":"7543_CR215","doi-asserted-by":"publisher","first-page":"e0121538","DOI":"10.1371\/journal.pone.0121538","volume":"10","author":"ZF Hong","year":"2015","unstructured":"Hong ZF et al (2015) Capsaicin enhances the drug sensitivity of cholangiocarcinoma through the Inhibition of chemotherapeutic-induced autophagy. PLoS ONE 10(5):e0121538. https:\/\/doi.org\/10.1371\/journal.pone.0121538","journal-title":"PLoS ONE"},{"issue":"3","key":"7543_CR216","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/JPET.117.243691","volume":"364","author":"JR Friedman","year":"2018","unstructured":"Friedman JR et al (2018) Anticancer activity of natural and synthetic capsaicin analogs. J Pharmacol Exp Ther 364(3):462\u2013473. https:\/\/doi.org\/10.1124\/JPET.117.243691","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"7543_CR217","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1080\/01635581.2020.1733623","volume":"72","author":"H Yang","year":"2020","unstructured":"Yang H et al (2020) Risk factors of esophageal squamous cell cancer specific for different macroscopic types. Nutr Cancer 72(8):1336\u20131344. https:\/\/doi.org\/10.1080\/01635581.2020.1733623","journal-title":"Nutr Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07543-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:00:16Z","timestamp":1664280016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":217,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7543"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07543-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}